8-K/AEarnings & Results

BRISTOL MYERS SQUIBB CO 8-K/A Report, Financial Results (Feb 19, 2008)

Filed February 19, 2008For Securities:BMYCELG-RIBMYMP

Summary

This 8-K/A filing from Bristol-Myers Squibb Company (BMY) serves as an amendment to a previous filing from January 31, 2008, which announced the company's fourth quarter and full-year financial results for 2007. The primary purpose of this amendment is to correct a computational error identified in the calculation of the Pharmaceuticals segment's gross profit and gross margin for the 2006 annual and quarterly periods, as presented in supplemental information. Importantly, the company states that this error did not affect its consolidated financial results or the 2007 gross profit and gross margin figures for the Pharmaceuticals segment. The filing provides a table detailing the 'as reported' versus 'corrected' figures for 2006, showing some variations in both gross profit and gross margin. The company also reiterates its use of non-GAAP financial information, adjusted to exclude restructuring items, to provide investors with a clearer view of ongoing operational performance.

Key Highlights

  • 1Amendment to a prior 8-K filing announcing Q4 and full-year 2007 results.
  • 2Identified a computational error in the 2006 gross profit and gross margin calculations for the Pharmaceuticals segment.
  • 3The error impacted supplemental information and not the company's consolidated financial results.
  • 4Corrected 2006 Pharmaceuticals segment gross profit and gross margin figures are provided.
  • 5The error did not affect the 2007 Pharmaceuticals segment gross profit or gross margin.
  • 6Reiteration of the use of non-GAAP financial information to present ongoing operational performance.

Frequently Asked Questions

This filing is an amendment to correct a computational error identified in the supplemental financial information provided in a previous 8-K filing. Specifically, the error related to the calculation of the Pharmaceuticals segment's gross profit and gross margin for the 2006 fiscal year.

No, the company explicitly states that this computational error did not affect its consolidated financial results. It also did not impact the calculation of GAAP and non-GAAP gross profit and gross margin for the Pharmaceuticals segment for the 2007 annual and quarterly periods.

The error was found in the supplemental information regarding the Pharmaceuticals segment's gross profit and gross margin for the 2006 annual and quarterly periods. This included both GAAP and non-GAAP figures.

Bristol-Myers Squibb uses non-GAAP financial information, adjusted to exclude items like restructuring costs, to enhance investors' understanding of the company's past performance and future prospects. It's presented as an indicator of the segment's baseline margin before certain items not considered reflective of ongoing results, and is used internally for performance evaluation and planning.